Pancreatic Cancer Research

ResearcherShandong UniversityNo recent work listed

Sanyuan Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0546-9778; OpenAlex author ID A5009712162. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 3 papers

Papers 12

  1. Exosomal linc-ROR mediates crosstalk between cancer cells and adipocytes to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.001↗
  2. Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.748442↗
  3. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review). Co-author DOI 10.3892/or.2021.7977↗
  4. Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. Co-author DOI 10.1016/j.pan.2019.08.008↗
  5. Immunotherapy for pancreatic cancer: A long and hopeful journey. Co-author DOI 10.1016/j.canlet.2018.03.040↗
  6. MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer. Last author DOI 10.1080/21691401.2017.1315429↗
  7. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Co-author DOI 10.1002/cam4.1071↗
  8. Early detection of pancreatic cancer: Where are we now and where are we going? Co-author DOI 10.1002/ijc.30670↗
  9. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Last author DOI 10.1016/j.canlet.2017.01.041↗
  10. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Last author DOI 10.1016/j.canlet.2016.02.018↗
  11. Pancreatic cancer stem cells: new insight into a stubborn disease. Last author DOI 10.1016/j.canlet.2014.12.004↗
  12. Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. Last author DOI 10.1186/s12957-015-0510-0↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianwei Xu · 10 shared papers, 2015–2021 · strength 0.87
  2. Hanxiang Zhan · 7 shared papers, 2015–2019 · strength 0.53
  3. Lei Wang · 5 shared papers, 2017–2021 · strength 0.49
  4. Hanxiang Zhan · 3 shared papers, 2017–2021 · strength 0.37
  5. Guangyong Zhang · 4 shared papers, 2015–2018 · strength 0.31
  6. Bin Zhou · 4 shared papers, 2016–2018 · strength 0.30
  7. Bin Zhou · 2 shared papers, 2019–2021 · strength 0.21
  8. Yunshan Wang · 2 shared papers, 2019–2021 · strength 0.21
  9. Xinshuang Yu · 1 shared paper, 2021 · strength 0.13
  10. Peng Dong · 1 shared paper, 2021 · strength 0.13
  11. Fengjun Liu · 1 shared paper, 2021 · strength 0.13
  12. Lei Wang · 2 shared papers, 2015–2016 · strength 0.12
  13. Jian Yang · 1 shared paper, 2021 · strength 0.12
  14. Bingyuan Zhang · 1 shared paper, 2021 · strength 0.12
  15. Yongzheng Li · 1 shared paper, 2021 · strength 0.12
  16. Zhaowei Sun · 1 shared paper, 2021 · strength 0.12
  17. Zhiyao Fan · 1 shared paper, 2021 · strength 0.12
  18. Feng Li · 1 shared paper, 2018 · strength 0.10
  19. Lei Wang · 1 shared paper, 2018 · strength 0.10
  20. Han Liu · 1 shared paper, 2019 · strength 0.10
  21. Taiping Zhang · 1 shared paper, 2015 · strength 0.06
  22. Ce Li · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.